PCDH19 Gene - Protocadherin 19

PCDH19 Gene - Protocadherin 19

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">PCDH19 Gene - Protocadherin 19</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td>PCDH19</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Protocadherin 19</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>Xq21.3</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td>[57526](https://www.ncbi.nlm.nih.gov/gene/57526)</td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td>[ENSG00000105369](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105369)</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>[300460](https://omim.org/entry/300460)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>[Q9Y6E0](https://www.uniprot.org/uniprot/Q9Y6E0)</td>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Protocadherin 19</td>
</tr>
<tr>
<td class="label">Protein Type</td>
<td>Cell adhesion molecule (cadherin superfamily)</td>
</tr>
<tr>
<td class="label">Exons</td>
<td>6</td>
</tr>
<tr>
<td class="label">Transcript</td>
<td>NM_001184931.2</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>1,135 amino acids</td>
</tr>
<tr>
<td class="label">Entity</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Academia</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Biotech (various)</td>
<td>Discovery</td>
</tr>
<tr>
<td clas

PCDH19 Gene - Protocadherin 19

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">PCDH19 Gene - Protocadherin 19</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td>PCDH19</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Protocadherin 19</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>Xq21.3</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td>[57526](https://www.ncbi.nlm.nih.gov/gene/57526)</td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td>[ENSG00000105369](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105369)</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>[300460](https://omim.org/entry/300460)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>[Q9Y6E0](https://www.uniprot.org/uniprot/Q9Y6E0)</td>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Protocadherin 19</td>
</tr>
<tr>
<td class="label">Protein Type</td>
<td>Cell adhesion molecule (cadherin superfamily)</td>
</tr>
<tr>
<td class="label">Exons</td>
<td>6</td>
</tr>
<tr>
<td class="label">Transcript</td>
<td>NM_001184931.2</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>1,135 amino acids</td>
</tr>
<tr>
<td class="label">Entity</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Academia</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Biotech (various)</td>
<td>Discovery</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

PCDH19 (Protocadherin 19) is an X-linked gene that encodes a cell adhesion protein belonging to the protocadherin family. Mutations in PCDH19 cause epilepsy-intellectual disability in females, representing one of the most common genetic causes of epilepsy in females. [@pcdh192008]

PCDH19 is part of the clustered protocadherin gene family, which includes PCDH1, PCDH1L, and other PCDH19-related genes arranged in a genomic cluster on chromosome Xq21.3. Unlike classical cadherins, protocadherins like PCDH19 exhibit highly specific expression patterns in the developing and adult brain, suggesting specialized roles in neural circuit formation and maintenance. [@pcdh192020]

Molecular Mechanism: Cell Adhesion Complex

PCDH19 mediates homophilic cell-cell adhesion—binding only to other PCDH19 molecules on adjacent cells. Emond et al. (2011) demonstrated that PCDH19 also forms a complex with N-cadherin (CDH2), creating a novel heterophilic adhesion mechanism that influences neural progenitor cell behavior during cortical development. This PCDH19-N-cadherin complex is thought to be critical for proper neuron migration and cortical layering. [@pcdh192020]

--- [@pcdh192013]
title: PCDH19 Gene
description: PCDH19 encodes a cell adhesion protein involved in neural development

Gene Overview

Mechanistic Model

The above model illustrates the cellular mosaicism hypothesis that uniquely explains PCDH19-related epilepsy pathogenesis in females. |

Function

PCDH19 encodes a transmembrane protein belonging to the protocadherin family, which is part of the cadherin superfamily of cell adhesion molecules. These proteins play critical roles in:

• Synapse formation and function: PCDH19 is involved in the formation and maintenance of synaptic connections between neurons
• Neural circuit development: The protein contributes to the development of neural circuits in the brain
• Cell-cell adhesion: As a cadherin family member, PCDH19 mediates homophilic cell-cell adhesion
• Dendrite morphogenesis: PCDH19 influences the branching and morphology of neuronal processes

Disease Association

PCDH19-Related Epilepsy (EFMR)

PCDH19-related epilepsy, also known as Epilepsy and Intellectual Disability in Females (EFMR), is an X-linked dominant disorder with unique inheritance characteristics.

Cellular Mechanism: The Mosaicism Hypothesis

The distinctive inheritance pattern of PCDH19-related epilepsy is explained by the cellular mosaicism hypothesis. Females are heterozygous for PCDH19 (one wild-type allele, one mutant allele). During early embryonic development, random X-chromosome inactivation creates patches of cells expressing either the mutant or wild-type allele. When mutant cells and wild-type cells come into contact during neural circuit formation, they fail to properly adhere, leading to impaired neuronal connectivity and seizure susceptibility. This "abnormal cell sorting" mechanism was demonstrated by Pederick et al. (2018), who showed that mosaic expression of mutant PCDH19 in female mouse brains leads to abnormal neural progenitor cell sorting and cortical malformation. [@pcdh192022]

Homan et al. (2018) further demonstrated that PCDH19 regulates neural progenitor cell differentiation, and loss of PCDH19 leads to asynchrony of neurogenesis—neurons are generated at abnormal times during development, contributing to circuit dysfunction. This mechanism explains why the disorder manifests even when the mutant allele should be silent due to X-inactivation. [@pcdh192021]

Recent work using human cortical organoids (2024) directly demonstrated abnormal cell sorting and altered early neurogenesis in PCDH19-mutant models, confirming the cellular mosaicism hypothesis in human tissue. [@pcdh192024]

Clinical Features

• Seizure onset: Typically between 6 months and 5 years of age
• Seizure types: Multiple types including focal seizures, generalized seizures, febrile seizures, and sometimes infantile spasms
• Intellectual disability: Variable severity, ranging from mild to moderate
• Behavioral issues: Autism spectrum features, attention deficits
• Gender pattern: Primarily affects females; males can be affected through different mechanisms (somatic mosaicism or genetic mechanisms)

Inheritance Pattern

PCDH19 shows an unusual X-linked inheritance pattern:

• Female heterozygous: Usually affected due to random X-chromosome inactivation
• Male hemizygous: Typically unaffected carriers (except in mosaic cases)
• Mosaic males: Rare cases of affected males with somatic mosaicism

Prevalence

PCDH19 is one of the most common genes associated with genetic epilepsy, accounting for approximately 5-10% of female patients with early-onset epilepsy and intellectual disability. [@pcdh192008]

A 2024 Chinese cohort study characterized 72 patients with PCDH19 clustering epilepsy, finding phenotypic diversity including early seizure onset, varying intellectual disability, and autism spectrum disorder in approximately 30% of patients. [@pcdh192017]

Diagnosis

Diagnostic confirmation requires molecular genetic testing—either gene panel testing or whole-exome sequencing—to identify pathogenic PCDH19 variants. Notably, over 100 distinct pathogenic variants have been reported, including missense, nonsense, frameshift, and splice-site mutations. [@pcdh192016]

EEG findings in PCDH19-related epilepsy typically show:

• Multifocal epileptiform discharges
• Seizure clusters with focal to bilateral tonic-clonic seizures
• Photosensitivity in some patients

Treatment Response

A 2025 systematic review found that PCDH19-related epilepsy is notoriously treatment-resistant. CommonASM use includes valproate, levetiracetam, and clonazepam. Notably, Levetiracetam has shown efficacy in suppressing seizure clusters in some patients. [@pcdh192023]

Corticosteroids (ACTH or oral steroids) have been used successfully in some cases to suppress seizure clusters. [@pcdh192018]

Surgical intervention (hemispherotomy or laser ablation) has been considered for refractory cases with focal cortical dysplasia. [@pcdh192018]

Gene Therapy Considerations

Technical Challenges

• Gene size: PCDH19 coding sequence (~2.5kb) fits well within AAV capacity
• Cell targeting: Must target excitatory neurons in cortical and limbic structures
• Delivery: CNS delivery required — similar challenges to other NDE gene therapies

Current Programs

Therapeutic Approaches Under Investigation

Structural Biology

Protein Structure

PCDH19 encodes a type I transmembrane protein of approximately 1,135 amino acids. The protein contains:

• Extracellular domain: Six cadherin repeats (EC1-EC6) that mediate homophilic binding
• Transmembrane domain: Single pass membrane-spanning helix
• Cytoplasmic tail: Intracellular domain that interacts with catenins and the actin cytoskeleton

Interaction Partners

• N-cadherin (CDH2): Heterophilic adhesion complex critical for neural development
• NONO: Paraspeckle protein that co-regulates gene expression with estrogen receptor alpha
• Actin cytoskeleton: Via β-catenin binding

Research Landscape

Key Publications

Animal Models

• Pcdh19 knockout and knock-in mouse models have been developed
• Zebrafish models used to study developmental phenotypes
• These models reproduce key features of the human disorder
• 2025 iPSC models show altered cytoskeleton dynamics in patient-derived neurons [@pcdh192027]

Synaptic Dysfunction

Mouse models have revealed female-specific synaptic dysfunction. Hoshina et al. (2021) demonstrated that Pcdh19 haploinsufficiency leads to impaired excitatory synaptic transmission specifically in female mice, mimicking the human female pattern of disease. This finding correlates with the observation that male patients (who lack the mosaic pattern due to having only one X chromosome) show different phenotypes than females. [@pcdh192025]

Cross-Links

• [SCN1A Gene](/genes/scn1a) — another common genetic epilepsy gene](/genes)
• [KCNQ2 Gene](/genes/kcnq2) — voltage-gated potassium channel for epilepsy](/genes)
• [CDKL5 Gene](/genes/cdkl5) — X-linked epilepsy gene](/genes)
• [GABRB3 Gene](/genes/gabrb3) — GABA-A receptor subunit in epilepsy](/genes)
• [AAV Gene Therapy for Neurodevelopmental Epilepsy](/therapeutics/aav-gene-therapy-neurodevelopmental-epilepsy)

Brain Atlas Resources

• [Allen Human Brain Atlas*: [Gene expression search](https://human.brain-map.org/microarray/search/show?search_term=PCDH19)](/datasets/allen-human-brain-atlas)](/datasets)
• [Allen Mouse Brain Atlas*: [Gene search](https://mouse.brain-map.org/search/index.html?query=PCDH19)](/projects/brain-atlas)](/projects)
• [Allen Cell Type Atlas*: [Transcriptomic cell type reference](https://portal.brain-map.org/atlases-and-data/rnaseq)](/cell-types/atlas)
• [BrainSpan Developmental Transcriptome*: [Developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=PCDH19)](/projects/brainspan)

References

[^pcdh192008]: [Depienne C, et al. (2009). PCDH19 mutations in girls causing epilepsy and intellectual disability. Depienne C, et al.. 2009](https://pubmed.ncbi.nlm.nih.gov/19109053/)
[^pcdh192013]: [Kaminski RM, et al. (2018). Targeting PCDH19 for epilepsy therapy. Kaminski RM, et al.. 2018](https://pubmed.ncbi.nlm.nih.gov/29867125/)
[^pcdh192015]: [Sanchez-Espino LF, et al. (2019). PCDH19-associated epilepsy: clinical features and therapeutic opportunities. Sanchez-Espino LF, et al.. 2019](https://pubmed.ncbi.nlm.nih.gov/31154478/)
[^pcdh192016]: [Samanta D. (2020). PCDH19-Related Epilepsy Syndrome: A Comprehensive Clinical Review. Mol Syndromol. 2020](https://pubmed.ncbi.nlm.nih.gov/32057594/)
[^pcdh192017]: [Kowkabi S, et al. (2024). PCDH19-clustering epilepsy, pathophysiology and clinical significance. Seizure. 2024](https://pubmed.ncbi.nlm.nih.gov/38521028/)
[^pcdh192018]: [Gecz J, Thomas PQ. (2020). Disentangling the paradox of the PCDH19 clustering epilepsy, a disorder of cellular mosaics. Neurosci Biobehav Rev. 2020](https://pubmed.ncbi.nlm.nih.gov/32726744/)
[^pcdh192019]: [Alaverdian D, et al. (2023). Modeling PCDH19 clustering epilepsy by Neurogenin 2 induction of patient-derived induced pluripotent stem cells. Stem Cell Reports. 2023](https://pubmed.ncbi.nlm.nih.gov/37186408/)
[^pcdh192020]: [Emond MR, et al. (2011). A complex of Protocadherin-19 and N-cadherin mediates a novel mechanism of cell adhesion. J Biol Chem. 2011](https://pubmed.ncbi.nlm.nih.gov/22184198/)
[^pcdh192021]: [Homan CC, et al. (2018). PCDH19 regulation of neural progenitor cell differentiation suggests asynchrony of neurogenesis as a mechanism contributing to PCDH19 Girls Clustering Epilepsy. Hum Mol Genet. 2018](https://pubmed.ncbi.nlm.nih.gov/29763708/)
[^pcdh192022]: [Pederick DT, et al. (2018). Abnormal Cell Sorting Underlies the Unique X-Linked Inheritance of PCDH19 Epilepsy. Cell Rep. 2018](https://pubmed.ncbi.nlm.nih.gov/29301106/)
[^pcdh192023]: [Tobiasz A, et al. (2025). Tough to treat: What we know about managing PCDH19-related epilepsy - Systematic review. Seizure. 2025](https://pubmed.ncbi.nlm.nih.gov/40934839/)
[^pcdh192024]: [Niu W, et al. (2024). Abnormal cell sorting and altered early neurogenesis in a human cortical organoid model of Protocadherin-19 clustering epilepsy. Brain. 2024](https://pubmed.ncbi.nlm.nih.gov/38638299/)
[^pcdh192025]: [Hoshina N, et al. (2021). Female-specific synaptic dysfunction and cognitive impairment in a mouse model of PCDH19 disorder. Mol Brain. 2021](https://pubmed.ncbi.nlm.nih.gov/33859005/)
[^pcdh192026]: [Cooper SR, et al. (2016). Structural determinants of adhesion by Protocadherin-19 and implications for its role in epilepsy. Structure. 2016](https://pubmed.ncbi.nlm.nih.gov/27787195/)
[^pcdh192027]: [Borghi R, et al. (2025). Altered cytoskeleton dynamics in patient-derived iPSC-based model of PCDH19 clustering epilepsy. Cell Mol Life Sci. 2025](https://pubmed.ncbi.nlm.nih.gov/39834389/)